Pharmacogenomics of endocrine therapy in breast cancer

James N. Ingle

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


The most important modality of treatment in the two-thirds of patients with an estrogen receptor (ER)-positive early breast cancer is endocrine therapy. In postmenopausal women, options include the selective ER modulators (SERMs), tamoxifen and raloxifene, and the 'third-generation' aromatase inhibitors (AIs), anastrozole, exemestane and letrozole. Under the auspices of the National Institutes of Health Global Alliance for Pharmacogenomics, Japan, the Mayo Clinic Pharmacogenomics Research Network Center and the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs. On the basis of the results of the GWAS, scientists at the Mayo Clinic have proceeded with functional genomic laboratory studies. As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer.

Original languageEnglish (US)
Pages (from-to)306-312
Number of pages7
JournalJournal of Human Genetics
Issue number6
StatePublished - Jun 2013


  • aromatase inhibitors
  • breast cancer
  • pharmacogenomics
  • tamoxifen

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Pharmacogenomics of endocrine therapy in breast cancer'. Together they form a unique fingerprint.

Cite this